New treatment methods for myocardial infarction
B Sun, L Wang, W Guo, S Chen, Y Ma… - Frontiers in …, 2023 - frontiersin.org
For a long time, cardiovascular clinicians have focused their research on coronary
atherosclerotic cardiovascular disease and acute myocardial infarction due to their high …
atherosclerotic cardiovascular disease and acute myocardial infarction due to their high …
Inflammatory and anti‐inflammatory cytokines in chronic heart failure: potential therapeutic implications
P Aukrust, L Gullestad, T Ueland, JK Damås… - Annals of …, 2005 - Taylor & Francis
Persistent inflammation, involving increased levels of inflammatory cytokines, seems to play
a pathogenic role in chronic heart failure (HF) by influencing heart contractility, inducing …
a pathogenic role in chronic heart failure (HF) by influencing heart contractility, inducing …
Repair after myocardial infarction, between fantasy and reality: the role of chemokines
EA Liehn, O Postea, A Curaj, N Marx - Journal of the American College of …, 2011 - jacc.org
Despite considerable progress over the last decades, acute myocardial infarction continues
to remain the major cause of morbidity and mortality worldwide. The present therapies …
to remain the major cause of morbidity and mortality worldwide. The present therapies …
Biologic effects and basic science of a novel immune-modulation therapy
AE Bolton - The American journal of cardiology, 2005 - Elsevier
The immune system is a system of dynamic equilibrium, with inflammatory responses
(mediated by T helper type 1 cells, interleukin [IL]-1β, interferon-γ, and tumor necrosis factor …
(mediated by T helper type 1 cells, interleukin [IL]-1β, interferon-γ, and tumor necrosis factor …
Therapeutic relevance of altered cytokine expression
KM Kulmatycki, F Jamali - Cytokine, 2001 - Elsevier
Cytokines and their receptors have numerous physiological functions. Altered
concentrations of these mediators are associated with various afflictions. For example, over …
concentrations of these mediators are associated with various afflictions. For example, over …
Inflammatory cytokines and postmyocardial infarction remodeling
M Nian, P Lee, N Khaper, P Liu - Circulation research, 2004 - Am Heart Assoc
Inflammatory response and cytokine elaboration are particularly active after myocardial
infarction and contribute to cardiac remodeling and eventual host outcome. The triggers of …
infarction and contribute to cardiac remodeling and eventual host outcome. The triggers of …
Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy?
R Celis, G Torre-Martinez… - Current Opinion in …, 2008 - journals.lww.com
There is substantial evidence of immune modulation promoting the downregulation of
inflammatory cytokines thus increasing several important and potentially therapeutic anti …
inflammatory cytokines thus increasing several important and potentially therapeutic anti …
Cytokines and cardiomyocyte death
KJ Pulkki - Annals of Medicine, 1997 - Taylor & Francis
Cytokines have been associated with the pathogenesis of acute coronary syndromes and
chronic heart failure (CHF), which are both associated with cardiomyocyte loss. In CHF …
chronic heart failure (CHF), which are both associated with cardiomyocyte loss. In CHF …
Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction
O Kleveland, T Ueland, G Kunszt, M Bratlie… - International Journal of …, 2018 - Elsevier
Aim To evaluate the effect of interleukin-6 inhibition with tocilizumab on the cytokine network
in patients with acute non-ST-elevation myocardial infarction (NSTEMI). Methods 117 …
in patients with acute non-ST-elevation myocardial infarction (NSTEMI). Methods 117 …
Use of interleukin-1 blockers in pericardial and cardiovascular diseases
Abstract Purpose of Review This review aims to summarize the role of the interleukin-1 (IL-1)
blocking agents in cardiovascular diseases, briefly describing the pathogenetic rationale …
blocking agents in cardiovascular diseases, briefly describing the pathogenetic rationale …